The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Eli Lilly's oral GLP-1 agonist Foundayo for weight management and type 2 diabetes. The approval makes the UK the first ...

Actio is the third acquisition for Jazz in the last few years, coming after it bought Chimerix for $935 million last year and ...

Ex-BioNTech chief strategy officer Ryan Richardson is chief executive of the new outfit, which launches with $25 million in ...

Novo Nordisk has joined forces with Amazon Web Services (AWS) on a project that will lead to the creation of an AI ...

The EU’s Joint Clinical Assessment (JCA), introduced 12th January 2025 under the EU Health Technology Assessment (HTA) ...

The team at the Mass General Brigham Neuroscience Institute found that fewer than 3% of 267 people with Alzheimer's assessed ...

The Sweden-headquartered group is paying $75 million upfront to France's Innate in order to partner lacutamab, which is vying ...

Welcome to the third edition of the pharmaphorum Clinical Trials Round-Up for 2026. May and June delivered a plethora of clinical trial updates. In the build-up to ASCO in June, our inbox was ...

Topline results from the phase 3 LEVEL trial of TNX-103, an oral formulation of calcium sensitiser levosimendan, showed that the drug was unable to improve how far patients with pulmonary hypertension ...

A Netherlands-based compounding pharmacy has been ordered to stop distributing a compounded nasal spray formulation of Novo Nordisk's GLP-1 agonist semaglutide in a test of the country's pharmacy ...

UK biotech OMass Therapeutics has revealed its first major pharma partnership, with Roche's Genentech unit paying $20 million upfront to tap into its expertise and find small-molecule therapies for ...

Moderna has announced a new cost-cutting round as it tries to pare down its annual costs, with a new commitment to cut 10% off its headcount by the end of the year. The target is to reduce its ...